Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: An observational study
International Journal of Infectious Diseases, Volume 20, No. 1, Year 2014
Notification
URL copied to clipboard!
Description
Background: The Middle East respiratory syndrome coronavirus (MERS-CoV) has been reported to have a high case-fatality rate. Currently, there is no specific therapy or vaccine with proven effectiveness for MERS-CoV infections. Methods: A combination of ribavirin and interferon therapy was used for the treatment of five MERS-CoV-positive patients. We reviewed the therapeutic schedule and the outcome of these patients. Results: All patients were critically ill with acute respiratory distress syndrome treated with adjunctive corticosteroids and were on mechanical ventilation at the time of initiation of therapy. The median time from admission to therapy with ribavirin and interferon was 19 (range 10-22) days. None of the patients responded to the supportive or therapeutic interventions and all died of their illness. Conclusions: While ribavirin and interferon may be effective in some patients, our practical experience suggests that critically ill patients with multiple comorbidities who are diagnosed late in the course of their illness may not benefit from combination antiviral therapy as preclinical data suggest. There is clearly an urgent need for a novel effective antiviral therapy for this emerging global threat. © 2014 The Authors.
Authors & Co-Authors
Al-Tawfiq, Jaffar Ali
Saudi Arabia, Dhahran
Johns Hopkins Aramco Healthcare
United States, Indianapolis
Indiana University School of Medicine
Momattin, Hisham
Saudi Arabia, Dhahran
Johns Hopkins Aramco Healthcare
Dib, Jean
Saudi Arabia, Dhahran
Johns Hopkins Aramco Healthcare
Al Memish, Ziad Ahmed
Saudi Arabia, Riyadh
Ministry of Health Saudi Arabia
Saudi Arabia, Riyadh
Alfaisal University
Statistics
Citations: 320
Authors: 4
Affiliations: 4
Identifiers
Doi:
10.1016/j.ijid.2013.12.003
ISSN:
12019712
e-ISSN:
18783511
Research Areas
Covid